Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF Eye Drops for Dry Eye in Glaucoma
2024-519460-40-00Phase 4Authorised
- Sponsor
- BTI Biotechnology Institute
- Start
- Nov 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of PRGF-Endoret in dry eye syndrome (DED) (2 arms), sponsored by BTI Biotechnology Institute. Primary endpoints: Change in ocular staining at 6 months and Change in OSDI symptom score at 6 months. Planned start Nov 2024; status: authorised.
02
Drugs
PRGF-Endoret
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2024-519460-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519460-40-00.